BioSpace News Archive

Healthcare Finance Direct (HFD), a leading FinTech company, and Enova Decisions, an analytics company, today announced a strategic partnership to build the new standard of patient underwriting for elective healthcare providers.

GW Pharmaceuticals plc (NASDAQ: GWPH, GW or the Company), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will host a virtual event for investors to provide a review of the U.S. development program and market opportunity for its late stage pipeline product, nabiximols.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will participate in the 40th Annual William Blair Growth Stock Conference,

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that its supplemental New Drug Application (sNDA) for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease (PD) patients receiving levodopa-based therapy has been accepted for review by the U.S. Food and Drug Administration (FDA)

Today, the U.S. Food and Drug Administration approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.

A global leader in the fight against cancer, The Leukemia & Lymphoma Society (LLS) announced today a $100,000 donation by the Press On Fund to support LLS’s assault on pediatric cancer.

NorthStar Healthcare Income, Inc. (“NorthStar Healthcare”) announced today that its 2020 annual meeting of stockholders (the “Annual Meeting”) will be held as a virtual-only meeting at https://viewproxy.com/northstar/2020/ on the previously announced date and time of Thursday, June 18, 2020 at 9:00 a.m

Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373,

John Wiley & Sons, Inc. (NYSE: JWA) (NYSE: JWB), a global leader in research and education, will release its fourth quarter and fiscal 2020 results prior to market open on Thursday, June 11, 2020.